Logo image of SLNO

SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

NASDAQ:SLNO - Nasdaq - US8342033094 - Common Stock - Currency: USD

77.47  +0.69 (+0.9%)

Fundamental Rating

2

Taking everything into account, SLNO scores 2 out of 10 in our fundamental rating. SLNO was compared to 562 industry peers in the Biotechnology industry. The financial health of SLNO is average, but there are quite some concerns on its profitability. SLNO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SLNO had negative earnings in the past year.
SLNO had a negative operating cash flow in the past year.
SLNO had negative earnings in each of the past 5 years.
In the past 5 years SLNO always reported negative operating cash flow.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of SLNO (-53.13%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -71.74%, SLNO is in line with its industry, outperforming 54.27% of the companies in the same industry.
Industry RankSector Rank
ROA -53.13%
ROE -71.74%
ROIC N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLNO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for SLNO has been increased compared to 1 year ago.
Compared to 5 years ago, SLNO has more shares outstanding
The debt/assets ratio for SLNO is higher compared to a year ago.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 23.99 indicates that SLNO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 23.99, SLNO belongs to the top of the industry, outperforming 95.55% of the companies in the same industry.
SLNO has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
SLNO has a worse Debt to Equity ratio (0.20) than 69.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 23.99
ROIC/WACCN/A
WACCN/A
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

SLNO has a Current Ratio of 15.68. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SLNO (15.68) is better than 90.93% of its industry peers.
SLNO has a Quick Ratio of 15.68. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
SLNO has a Quick ratio of 15.68. This is amongst the best in the industry. SLNO outperforms 90.93% of its industry peers.
Industry RankSector Rank
Current Ratio 15.68
Quick Ratio 15.68
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

SLNO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -72.39%.
EPS 1Y (TTM)-72.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SLNO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.87% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.26%
EPS Next 2Y43.76%
EPS Next 3Y42.87%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 100M 200M 300M 400M
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLNO. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 272.65 indicates a quite expensive valuation of SLNO.
Based on the Price/Forward Earnings ratio, SLNO is valued cheaper than 87.72% of the companies in the same industry.
SLNO's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 20.44.
Industry RankSector Rank
PE N/A
Fwd PE 272.65
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200 250

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
SLNO's earnings are expected to grow with 42.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.76%
EPS Next 3Y42.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLNO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (5/12/2025, 11:06:08 AM)

77.47

+0.69 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners114.62%
Inst Owner Change0.15%
Ins Owners2.48%
Ins Owner Change-10.09%
Market Cap3.87B
Analysts86.67
Price Target107.67 (38.98%)
Short Float %11.73%
Short Ratio3.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-97.22%
Min EPS beat(2)-186.49%
Max EPS beat(2)-7.96%
EPS beat(4)1
Avg EPS beat(4)-61.22%
Min EPS beat(4)-186.49%
Max EPS beat(4)6.6%
EPS beat(8)2
Avg EPS beat(8)-42.48%
EPS beat(12)5
Avg EPS beat(12)-24.3%
EPS beat(16)7
Avg EPS beat(16)-18.52%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.45%
PT rev (3m)42.09%
EPS NQ rev (1m)-11.24%
EPS NQ rev (3m)-23.26%
EPS NY rev (1m)-6.12%
EPS NY rev (3m)-5.28%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)24.02%
Revenue NY rev (3m)24.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 272.65
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 15.77
P/tB 16.22
EV/EBITDA N/A
EPS(TTM)-4.62
EYN/A
EPS(NY)0.28
Fwd EY0.37%
FCF(TTM)-1.39
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0
BVpS4.91
TBVpS4.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.13%
ROE -71.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.97%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.68
Quick Ratio 15.68
Altman-Z 23.99
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.83%
Cap/Depr(5y)2.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.02%
EPS Next Y30.26%
EPS Next 2Y43.76%
EPS Next 3Y42.87%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-353.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-177.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-177.05%
OCF growth 3YN/A
OCF growth 5YN/A